Nothing Special   »   [go: up one dir, main page]

MA33537B1 - Anticorps anti-cdcp1 humanisés - Google Patents

Anticorps anti-cdcp1 humanisés

Info

Publication number
MA33537B1
MA33537B1 MA34651A MA34651A MA33537B1 MA 33537 B1 MA33537 B1 MA 33537B1 MA 34651 A MA34651 A MA 34651A MA 34651 A MA34651 A MA 34651A MA 33537 B1 MA33537 B1 MA 33537B1
Authority
MA
Morocco
Prior art keywords
against human
antibodies against
antibodies
cdcp1
human cdcp1
Prior art date
Application number
MA34651A
Other languages
Arabic (ar)
English (en)
Inventor
Johannes Auer
Birgit Bossenmaier
Guy Georges
Alexander Lifke
Ekkehard Moessner
Gerhard Niederfellner
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of MA33537B1 publication Critical patent/MA33537B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des anticorps humanisés contre le cdcp1 humain (anticorps anti-cdcp1), des procédés de production desdits anticorps, des compositions pharmaceutiques contenant lesdits anticorps, et des utilisations de ceux-ci.
MA34651A 2009-08-28 2012-02-27 Anticorps anti-cdcp1 humanisés MA33537B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09011046 2009-08-28
EP10000972 2010-02-01
PCT/EP2010/005244 WO2011023389A1 (fr) 2009-08-28 2010-08-26 Anticorps anti-cdcp1 humanisés

Publications (1)

Publication Number Publication Date
MA33537B1 true MA33537B1 (fr) 2012-08-01

Family

ID=43086176

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34651A MA33537B1 (fr) 2009-08-28 2012-02-27 Anticorps anti-cdcp1 humanisés

Country Status (24)

Country Link
US (2) US8394928B2 (fr)
EP (1) EP2470567A1 (fr)
JP (1) JP5647687B2 (fr)
KR (1) KR101495407B1 (fr)
CN (1) CN102482357B (fr)
AR (1) AR077973A1 (fr)
AU (1) AU2010288879A1 (fr)
BR (1) BR112012004221A2 (fr)
CA (1) CA2770161A1 (fr)
CL (1) CL2012000524A1 (fr)
CO (1) CO6511201A2 (fr)
CR (1) CR20120038A (fr)
EC (1) ECSP12011701A (fr)
HK (1) HK1167412A1 (fr)
IL (1) IL217919A0 (fr)
MA (1) MA33537B1 (fr)
MX (1) MX2012002458A (fr)
NZ (1) NZ597664A (fr)
PE (1) PE20121063A1 (fr)
RU (1) RU2571207C2 (fr)
SG (1) SG178886A1 (fr)
TW (1) TWI412375B (fr)
UA (1) UA106890C2 (fr)
WO (1) WO2011023389A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201113037A (en) * 2009-08-28 2011-04-16 Hoffmann La Roche Antibodies against CDCP1 for the treatment of cancer
TWI412375B (zh) * 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
KR20130118941A (ko) 2011-02-10 2013-10-30 로슈 글리카트 아게 면역치료법
EP2882777B1 (fr) 2012-08-07 2018-10-10 Roche Glycart AG Composition comprenant deux anticorps génétiquement modifiés pour avoir une fonction effectrice réduite et accrue
EP2928923B1 (fr) 2012-12-10 2020-01-22 Biogen MA Inc. Anticorps anti-antigène 2 de cellules dendritiques sanguines et ses utilisations
WO2014172448A2 (fr) * 2013-04-17 2014-10-23 Anaptysbio, Inc. Anticorps diriges contre le recepteur d'activine de type ii (actrii)
WO2015082446A1 (fr) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Traitement du cancer à l'aide d'un anticorps anti-cdcp1 et d'un taxane
RU2016134256A (ru) * 2014-01-24 2018-03-05 Дзе Генри М. Джексон Фаундейшн Фор Дзе Эдвансмент Оф Милитари Медсин, Инк. Антитела против f гликопротеина вирусов хендра и нипах
WO2015200522A2 (fr) * 2014-06-25 2015-12-30 Integrated Biotherapeutics, Inc. Anticorps monoclonaux dirigés contre des glycoprotéines d'enveloppe de multiples espèces de filovirus
US11702481B2 (en) * 2016-12-16 2023-07-18 Bluefin Biomedicine, Inc. Anti-cub domain-containing protein 1 (CDCP1) antibodies, antibody drug conjugates, and methods of use thereof
US10928391B2 (en) * 2017-06-06 2021-02-23 The Cleveland Clinic Foundation CD318 as a marker for, and CD318 inhibition as a treatment for, autoimmune disease
WO2019084319A1 (fr) 2017-10-25 2019-05-02 The Regents Of The University Of California Anticorps contre cdcp1 pour le traitement et la détection du cancer
WO2020097336A1 (fr) * 2018-11-09 2020-05-14 Beth Israel Deaconess Medical Center Thérapies ciblant la cdcp1
MX2021009119A (es) * 2019-02-01 2022-01-18 Fond Per Listituto Oncologico Di Ricerca Ior Metodos de tratamiento contra el cancer de prostata resistente a la castracion.
CN118440203A (zh) * 2019-12-27 2024-08-06 凯奥目生物科学株式会社 抗cdcp1抗体
CN117264055A (zh) * 2022-06-14 2023-12-22 上海恒润达生生物科技股份有限公司 一种特异性结合人cd318的vhh抗体或其抗原结合片段及其制备方法和应用
WO2023246701A1 (fr) * 2022-06-20 2023-12-28 四川汇宇制药股份有限公司 Anticorps et son utilisation
WO2024013723A1 (fr) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd Conjugués anticorps-médicament qui se lient à cdcp1 et leurs utilisations
KR20240057529A (ko) * 2022-10-24 2024-05-03 주식회사 노벨티노빌리티 신규 항-cdcp1 항체 및 이의 용도

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
CA2267620A1 (fr) * 1996-07-16 1998-01-22 Andreas Pluckthun Domaines de la superfamille des immunoglobulines et fragments presentant une solubilite accrue
ES2340112T3 (es) 1998-04-20 2010-05-28 Glycart Biotechnology Ag Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos.
EP2278003B2 (fr) 1999-04-09 2020-08-05 Kyowa Kirin Co., Ltd. Procédé de contrôle de l'activité de molécule fonctionnelle immunologique
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
CN1329061A (zh) 2000-06-19 2002-01-02 上海博德基因开发有限公司 一种新的多肽——人g蛋白亚基9.46和编码这种多肽的多核苷酸
EP1301533A1 (fr) 2000-07-07 2003-04-16 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Antigene specifique de tumeur (b345) se caracterisant par une sequence d'acides amines telle que dans seq id no 4
PL217751B1 (pl) * 2001-08-03 2014-08-29 Glycart Biotechnology Ag Zastosowanie glikomodyfikowanego przeciwciała do wytwarzania kompozycji farmaceutycznej do leczenia choroby wybranej z grupy składającej się z nowotworu, małopłytkowości autoimmunologicznej w przewlekłej chorobie przeszczep przeciwko gospodarzowi i immunozależnej nabytej aplazji czysto czerwonokrwinkowej
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
DE10242146A1 (de) * 2002-09-04 2004-03-18 Eberhard-Karls-Universität Tübingen Universitätsklinikum Antikörper zur Identifizierung und/oder Isolierung von hämatopoetischen Stammzellen
SG179292A1 (en) 2003-01-22 2012-04-27 Roche Glycart Ag Fusion constructs and use of same to produce antibodies with increased fc receptor binding affinity and effector function
DE602004027992D1 (de) 2003-02-19 2010-08-19 Novartis Ag In metastatischen menschlichen tumorzellen exprimiertes glycoproteinantigen sima135
CA2534077A1 (fr) 2003-07-29 2005-02-10 Morphotek Inc. Anticorps et procedes permettant de produire des anticorps genetiquement modifies presentant une fonction effectrice amelioree
CA2536408A1 (fr) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Anticorps ameliores possedant une fonction d'effecteur modifiee et procedes de fabrication associes
JP2007504245A (ja) 2003-09-05 2007-03-01 ジェネンテック・インコーポレーテッド 変更したエフェクター機能を有する抗体
GB0324656D0 (en) 2003-10-22 2003-11-26 Celltech R&D Ltd A protein involved in ovarian cancer
NZ588860A (en) 2003-11-05 2012-03-30 Roche Glycart Ag CD20 antibodies with increased Fc receptor binding affinity and effector function
US20080008719A1 (en) * 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
WO2007024249A2 (fr) 2004-11-10 2007-03-01 Macrogenics, Inc. Fonction effectrice obtenue par creation par genie biologique de regions d'anticorps fc
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
CA2606102C (fr) 2005-04-26 2014-09-30 Medimmune, Inc. Modulation de la fonction d'effecteur d'anticorps par ingenierie de domaine "charniere"
JP5315489B2 (ja) 2005-04-26 2013-10-16 アール クレア アンド カンパニー エフェクター機能が増強されたヒトＩｇＧ抗体を作製する方法
US20070031419A1 (en) * 2005-06-30 2007-02-08 Applera Corporation Methods and compositions for treating diseases targeting CDCP1
RU2482132C2 (ru) 2005-08-26 2013-05-20 Роше Гликарт Аг Модифицированные антигенсвязывающие молекулы с измененной клеточной сигнальной активностью
JP2007112734A (ja) 2005-10-19 2007-05-10 Chugai Pharmaceut Co Ltd 抗ｃｄｃｐ１抗体を含有する癌細胞増殖抑制剤
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
TWI412375B (zh) * 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體

Also Published As

Publication number Publication date
NZ597664A (en) 2013-03-28
CO6511201A2 (es) 2012-08-31
CR20120038A (es) 2012-04-18
TWI412375B (zh) 2013-10-21
CN102482357A (zh) 2012-05-30
ECSP12011701A (es) 2012-03-30
JP5647687B2 (ja) 2015-01-07
US20110052582A1 (en) 2011-03-03
RU2571207C2 (ru) 2015-12-20
TW201110983A (en) 2011-04-01
UA106890C2 (uk) 2014-10-27
US9346886B2 (en) 2016-05-24
WO2011023389A1 (fr) 2011-03-03
JP2013502904A (ja) 2013-01-31
AR077973A1 (es) 2011-10-05
AU2010288879A1 (en) 2012-02-02
HK1167412A1 (en) 2012-11-30
SG178886A1 (en) 2012-04-27
KR101495407B1 (ko) 2015-02-24
CN102482357B (zh) 2014-06-11
CL2012000524A1 (es) 2012-08-17
MX2012002458A (es) 2012-03-14
US20130209455A1 (en) 2013-08-15
KR20120089658A (ko) 2012-08-13
CA2770161A1 (fr) 2011-03-03
EP2470567A1 (fr) 2012-07-04
RU2012111708A (ru) 2013-10-10
PE20121063A1 (es) 2012-08-09
IL217919A0 (en) 2012-03-29
US8394928B2 (en) 2013-03-12
BR112012004221A2 (pt) 2016-11-29

Similar Documents

Publication Publication Date Title
MA33537B1 (fr) Anticorps anti-cdcp1 humanisés
MA33892B1 (fr) Anticorps anti-her3, et leurs utilisations
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
MA32713B1 (fr) Anticorps anti-egfr/anti-igf-1r bispecifiques
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
CR9253A (es) Fijacion de la dosificacion de anticuerpos her
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
MA33208B1 (fr) Anticorps anti-fgfr3 et procédés d'utilisation de ceux-ci
MY171841A (en) Antibody formulation
MA34091B1 (fr) Anticorps anti-cd40
ATE427965T1 (de) Antikírper gegen 25-hydroxyvitamin d
AU2009301431A8 (en) Bispecific anti-VEGF/anti-ANG-2 antibodies
MA34172B1 (fr) Anticorps bispécifiques, bivalents anti-vegf/anti-ang-2
FR2883179B1 (fr) Comprime enrobe
CO6571886A2 (es) Antagonistas de pcsk9
PH12013502192A1 (en) Antibodies against human angiopoietin 2
MX340558B (es) Anticuerpos biespecificos que comprenden fragmento fv estabilizado con disulfuro.
MA33551B1 (fr) Anticorps anti-egfl1 humanises, et procedes d'utilisation correspondants
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
MA34722B1 (fr) Méthodes et compositions pour l'immunothérapie de maladies neurales
GB201303865D0 (en) Pharmaceutical composition and method of inhibiting of production or amplifyingelimination of P24 protein
EA201001353A1 (ru) Гидробромид ивабрадина